GLP-1 Incretin Reporter HEK 293 Cells - GLP-1 Bioassay

Cell line description

HEK-Blue™ GLP-1 cells were generated by stable transfection of the human embryonic kidney HEK293 cell line with the gene encoding human GLP-1 receptor (GLP-1R). In addition, a SEAP (secreted embryonic alkaline phosphatase) reporter gene under the control of a minimal promoter fused to nine cAMP response elements (CRE) was introduced. Binding of GLP-1 or a synthetic hormone receptor agonist to the GLP-1R on the surface of HEK-Blue™ GLP-1 cells triggers a signaling cascade leading to the activation of the CRE-binding Protein (CREB) pathway and the subsequent production of SEAP. This can be readily assessed in cell culture supernatant using QUANTI‑Blue™ Solution, a SEAP detection reagent. 

HEK‑Blue™ GLP-1 cells respond to human GLP-1 and other GLP1 receptor agonists, including Semaglutide, Orforglipron, Tirzepatide, and Retatrutide. They do not respond to other G protein-coupled receptor (GPCR)-activating hormones, such as GIP (glucose-dependent insulinotropic polypeptide) or glucagon. HEK-Blue™ GLP-1 cells express approximately 1,000 GLP-1 receptors per cell, a surface receptor density consistent with physiological levels reported in the literature [1,2].
 

Background

Incretins are gut-derived peptide hormones secreted after nutrient intake to enhance glucose-dependent insulin release from pancreatic β-cells. They have emerged as key therapeutic targets in diabetes and obesity research, inspiring the development of dual and triple receptor agonists that synergistically enhance glycemic control, promote weight loss, and improve overall metabolic health [3]. 

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced primarily by intestinal L-cells in response to food intake. It acts through the GLP-1 receptor (GLP-1R), a G protein-coupled receptor (GPCR) predominantly expressed in pancreatic β-cells, the gastrointestinal tract, and the central nervous system. Upon binding to GLP-1R, GLP-1 triggers the activation of the G protein, which stimulates adenylyl cyclase [4]. This leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP further activates the Protein kinase A (PKA), which subsequently translocates to the nucleus and phosphorylates cAMP response element binding protein (CREB). CREB is a central transcription factor involved in the expression of insulin and other genes required for glucose homeostasis [4]. Among its various biological activities, GLP-1 enhances glucose-dependent insulin secretion and suppresses glucagon release. It also promotes satiety by delaying gastric emptying and activating responses in the central nervous system. Beyond its metabolic functions, GLP-1 signaling has been implicated in cardiovascular protection and neurotrophic processes, highlighting its pleiotropic physiological roles [5]. 

GLP-1R agonists were developed as long-acting therapeutic agents to overcome the short half-life of endogenous GLP-1, namely Semaglutide (Ozempic®, Wegovy®, Rybelsus®). These compounds have demonstrated significant efficacy in improving glycemic control in patients with Type 2 diabetes (T2D) by enhancing insulin secretion and reducing glucagon release. In addition to their antidiabetic effects, GLP-1R agonists have shown substantial benefits in promoting weight loss, largely through appetite suppression and delayed gastric emptying. The success of these therapies has paved the way for the development of next-generation treatments, including multi-agonist molecules like Tirzepatide (Mounjaro/Zepbound) or Retatrutide (LY3437943) that simultaneously target several metabolic receptors to achieve improved metabolic outcomes in obese or diabetic patients [3,6]. These long-acting incretin receptor agonists have revolutionized the landscape of obesity and T2D research and are now being explored for other metabolic disorders, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) [3].

1. Fehmann HC & Habener JF., 1991. Functional receptors for glucagon-like peptide-1-(7-36)amide on a somatostatin secreting cell line. J Biol Chem. 266(33), 22490-22494.
2. Gros L et al., 1993.  Topochemistry of glucagon-like peptide-1-(7-36) amide receptor expression in the rat gastrointestinal tract and pancreas. Endocrinology. 133(2), 631-638.
3. Gutgesell RM, et al. 2024. Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. Diabetes Ther. 2024 May;15(5):1069-1084.
4. Zheng Z et al., 2024. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther. 9:234.
5. Drucker DJ, 2018. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 27(4):740-756.
6. Müller, T. D. et al., 2025 Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab. 95:102118.